OBP2A and obesity disorder: Obesity is associated with its downregulation, while LCN13 therapies in mice with either genetic or dietary obesity lead to an improvement in their hyperglycemia, hyperinsulinemia, insulin resistance, glucose intolerance, and hepatic steatosis [18, 19].